Celemics Inc. of Seoul at MEDICA 2020 in Düsseldorf -- COMPAMED Trade Fair
Manage stand orders
Select Option

Celemics Inc.

20F, BYC Highcity Bldg. A Gasandigital 1-ro 131, Geumcheon, 08506 Seoul
Korea, Republic

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Media files

Contact

Kevin Lim

Business Development Manager

Phone
+82-2-6966-0140

Email
kevin@celemics.com

John Yi

Business Development Manager

Phone
+82-2-6966-0155

Email
john@celemics.com

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.04  Other molecular diagnostics testing

Our products

Product category: Other molecular diagnostics testing

NGS Target Enrichment Panels

 “ Unlike Whole Genome Sequencing,
Targeted Sequencing is a technique that selectively analyzes specific regional sequences of genomes.”

Our Target Enrichment Panel uses hybridization-based capture technology to enable the core
process of Target Sequencing, which is the separation and analysis of specific regional sequences of
entire genomes. It is also able to accurately analyze all types of mutations, such as SNV, InDel CNV,
and Rearrangement.

Celemics’ Target Enrichment Panel utilizes our intrinsic probe design, rebalancing, and molecular
barcode technologies to efficiently analyze not only hard-to-capture areas such as GC-rich and
homologous regions but also samples originating from circulating tumor DNA and FFPE with extremely
small amounts of damaged DNA and RNA as well. We also provide our proprietary functionalities
to prevent sample cross-contamination.

For all Customized and Ready-to-Use Panels, Celemics uses standard DNA samples to run product QC for wet-lab tests, NGS runs, and bioinformatics up to the standard of the actual product used by our clients, and also provide detailed QC information as well.
Through this process, we can reduce both the possibility of experimental failure and the time and costs involved with our clients evaluating the products themselves. Additionally, through our proprietary 2-step mass production technology, we can manufacture high-quality reproducible customized panels, which makes first-time-user clients have their subsequent orders.

Celemics’ Target Enrichment Panel is compatible with all currently available NGS equipment, such as Illumina, Thermo Fisher Scientific, Pacific Bioscience, and MGI, and provides bioinformatics software for data analysis.

More Less

Product category: Other molecular diagnostics testing

BTSeq™ SARS-CoV-2 Sequencing Service

“Celemics has developed reagents and bioinformatics software specifically optimized to the amplification of the whole SARS-CoV-2 genome sequence, resulting in the provision of high-quality analysis results of the virus’s whole genome sequence within 24 hours”

The novel coronavirus (SARS-CoV-2) is currently spreading rapidly throughout the globe and is exerting a detrimental effect on the greater populace and their general quality of life. To combat the virus and aid in vaccine development, contact tracing, and virus research, the analysis of SARS-CoV-2’s whole genomic sequence has become absolutely necessary.

Celemics has developed reagents and bioinformatics software specifically optimized for the amplification of the whole SARS-CoV-2 genome sequence, resulting in the provision of high-quality analysis results of the virus’s whole genome sequence within 24 hours.

In most cases, RNA of the host cell is separated and purified along with viral RNA during extraction.
This leads to an excessive amount of data being required to perform typical Total RNA-seq compared to the entire viral genome, leading to low-quality data and high costs.

Celemics solves this issue by developing extremely uniform amplification technology and bioinformatics software, which in turn provides quality data by efficiently eliminating any gaps generated from bias in the RT-PCR step.

More Less

Product category: Other molecular diagnostics testing

BTSeq™ Contiguous Sequencing Service

“ We were also able to significantly lower the Library Prep processing and overall analysis costs by developing our own proprietary BTSeq™ Library Preparation reagents, as these factors occupied a significant portion of the cost of NGS analysis. ”

For the last few decades, Sanger Sequencing has been the standard for analyzing DNA sequences.
Due to its need for repetitive primer design, primer synthesis, and sequencing steps during Primer Walking when analyzing long sequences, however, it requires lengthy experimental time and large costs to perform.

Additionally, issues such as high re-experimentation rates, intermittent errors, and a less than 1 kb read length limitation have made sequence analysis difficult for clients.

To overcome these limitations, Celemics created an NGS-based molecular barcoding technology and NGS error elimination algorithm solution, allowing for the analysis of sequences with lengths greater than 1kb without the need of sequencing primers.

Using Celemics’ BTSeq™ Library Preparation reagents Contiguous Sequencing Service, clients are able to obtain accurate results, even from sequences that were difficult to read via Sanger Sequencing, such as those with strong secondary structures.

We were also able to significantly lower the Library Prep processing and overall analysis costs by developing our own proprietary BTPrep™ Library Preparation reagents, as these factors occupied a significant portion of the cost of NGS analysis.

More Less

Product category: Other molecular diagnostics testing

TrueRepertoire™ Sequencing Service

“ Celemics’ TrueRepertoire™ Solution overcomes the limitations of current antibody discovery methodologies and NGS-based immune repertoire analysis through ”

Because the in vitro screening method currently used in antibody discovery selects clones at random then proceeds with an assay, there is a high chance of repeated discovery for antibodies existing in large quantities and a low chance of discovery for antibodies of low frequencies with various characteristics and binding capacities.

In contrast, if the in vitro screening and DNA sequence analysis steps are switched to confirm the antibody sequences inside the library and their binding capacities are checked without repeating identical antibodies, clients are able to increase the number of clones with confirmed binding capacities and decrease the cost in relation to the number of confirmed clones when compared to ELISA analysis.

Therefore, clients can discover rare clones previously undetected with existing technology and are also able to drastically decrease the associated time and cost.

TrueRepertoire™ solution
1. Flawless analysis of an antibody library with over 10,000 sequences
2. Sequence analysis of the entire antibody variable area, including VL-VH Linkage information
3. Characteristic analysis and prediction of antibodies using specialized bioinformatics analysis
4. Retrieval of the client’s desired DNA antibody molecule
Through this, clients can discover rare clones previously undetected with existing technology and are also able to drastically decrease the associated time and cost.

More Less

About us

Company details

Celemics is a biomaterial technology company that uses DNA-based biomaterials and revolutionary sequencing technology to lead the way for the medical, pharmaceutical, microbiome,synthetic biology, and breeding fields.
Through its practical implementation into the aforementioned areas and various other biological R&D fields, Celemics hopes to rapidly advance the innovations made in medical and scientific technology and contribute to the safety and health of all.

1. Treatment Selection, Monitoring, and Early Diagnosis of Cancer
2. Diagnosis and Treatment Management of Rare Diseases
3. Vaccine Development, Research, and Propagation Tracking
4. Low-Cost, High-Efficiency Antibody Discovery and Strain Development
5. Microbiome Analysis

More Less

Company data

Number of employees

50-99

Foundation

2010

Company information as a PDF file